Patents - Global Data - Dimensions
Application
Highly potent ISVD compounds that can replace FVIII(a)
Applicants
- Novo Nordisk (Denmark)
[NORA names: Novo Nordisk; Private Research; Denmark; Europe, EU; Nordic; OECD]
Abstract
[Problem] The problem to be solved by the present invention is to provide improved compounds for the treatment of blood clotting disorders that can reduce the treatment burden and replace FVIII(a) for use in the treatment of blood clotting disorders, such as hemophilia A and related diseases. [Solution] The present invention relates to ISVD polypeptide derivatives capable of binding coagulation factors IX(a) and X(a), which are highly potent and provide a half-life long enough to allow effective subcutaneous and oral administration. [Selected Figures] None
Patent Family Records (6)
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
Novo Nordisk (Denmark), Novo Nordisk AS VEGGE ANDREAS, STEFFENSEN SOREN, BUYSE MARIE ANGE, (...more)
2024, US-20240067944-A1
HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
NOVO NORDISK AS, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, TW-202409091-A
Highly potent ISVD compounds capable of substituting for FVIII(a)
NOVO NORDISK A, Novo Nordisk (Denmark) VEGGE ANDREAS, FULLE SIMONE, NORRMAN MATHIAS, (...more)
2024, KR-20240007881-A
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-7459354-B2
Highly potent ISVD compounds that can replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS アンドレアス・ヴェッゲ, エヴァ・ヨハンソン, エヴリン・デ・タヴェルニエ, (...more)
2024, JP-2024073606-A
Highly Potent ISVD Compounds that Can Replace FVIII(a)
Novo Nordisk (Denmark), Novo Nordisk AS ANDREAS VEGGE, SIMONE FULLE, MATHIAS NORRMAN, (...more)
2024, JP-2024020151-A